Ranbaxy settled an eight-year dispute with the U.S. Food and Drug Administration (FDA) yesterday at the cost of $500 million.
Former director and global head of Research Information and Portfolio Management at Ranbaxy Laboratories, Dinesh Thakur, will go down in history as the man who brought down the Indian company in the United States’ most high-profile generic drug violation case in history. With the whistleblower’s help, the government was able to unravel years of falsified records and dangerous manufacturing practices within Ranbaxy, drawing attention to the need for better regulation of drugs sold in the U.S., regardless of where they are made. Thakur will receive $48.5 million for his efforts, according to Moneycontrol.com. More Ranbaxy Settles with FDA for $500 Million; Whistleblower to Get $48.5 Million